Use of prior vaccinations for the development of new vaccines.

There is currently a need for vaccine development to improve the immunogenicity of protective epitopes, which themselves are often poorly immunogenic. Although the immunogenicity of these epitopes can be enhanced by linking them to highly immunogenic carriers, such carriers derived from current vaccines have not proven to be generally effective. One reason may be related to epitope-specific suppression, in which prior vaccination with a protein can inhibit the antibody response to new epitopes linked to the protein. To circumvent such inhibition, a peptide from tetanus toxoid was identified that, when linked to a B cell epitope and injected into tetanus toxoid-primed recipients, retained sequences for carrier but not suppressor function. The antibody response to the B cell epitope was enhanced. This may be a general method for taking advantage of previous vaccinations in the development of new vaccines.

[1]  A. Allison,et al.  An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. , 1986, Journal of immunological methods.

[2]  V. Nussenzweig,et al.  Synthetic peptide vaccine confers protection against murine malaria , 1987, The Journal of experimental medicine.

[3]  G. Lewis,et al.  Purification of functional, determinant-specific, idiotype-bearing murine T cells , 1978, The Journal of experimental medicine.

[4]  H. Matile,et al.  Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults. , 1989, Vaccine.

[5]  A. Trzeciak,et al.  A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules , 1988, Nature.

[6]  N. K. Jerne,et al.  THE REQUIREMENT OF MORE THAN ONE ANTIGENIC DETERMINANT FOR IMMUNOGENICITY , 1969, The Journal of experimental medicine.

[7]  C DeLisi,et al.  T-cell antigenic sites tend to be amphipathic structures. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[9]  M. Jolivet,et al.  Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier , 1987, Infection and immunity.

[10]  G. Welling,et al.  The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. , 1989, Journal of immunological methods.

[11]  Y. Fedon,et al.  Engineering of immunogenic peptides by co‐linear synthesis of determinants recognized by B and T cells , 1987, European journal of immunology.

[12]  E. Sercarz,et al.  Different Functional Specificity Repertoires for Suppressor and Helper T Cells , 1978, Immunological reviews.

[13]  J. Weber,et al.  Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. , 1984, Science.

[14]  A. Trzeciak,et al.  Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. , 1988, Journal of immunology.

[15]  C. Leclerc,et al.  Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. , 1985, Journal of immunology.

[16]  A. Trzeciak,et al.  Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, P. falciparum. , 1988, Immunology.

[17]  Myron M. Levine,et al.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites , 1987, Nature.

[18]  V. Nussenzweig,et al.  Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. , 1985, Science.

[19]  A. Miller,et al.  Fine specificity of regulatory T cells. II. Suppressor and helper T cells are induced by different regions of hen egg-white lysozyme in a genetically nonresponder mouse strain , 1979, The Journal of experimental medicine.

[20]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.

[21]  N. Mitchison,et al.  The carrier effect in the secondary response to hapten‐protein conjugates. I. Measurement of the effect with transferred cells and objections to the local environment hypothesis , 1971, European journal of immunology.

[22]  P. Lambert,et al.  The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines. , 1986, Journal of immunology.

[23]  M. Bevan,et al.  Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization , 1989, The Journal of experimental medicine.

[24]  S. Puri,et al.  Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses , 1982, The Journal of experimental medicine.

[25]  M. Sela,et al.  Effect of carrier on the immunogenic capacity of synthetic cholera vaccine. , 1985, Molecular immunology.

[26]  S. Jonjić,et al.  Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes , 1989, The Journal of experimental medicine.

[27]  C. Leclerc,et al.  Epitopic suppression in synthetic vaccine models: analysis of the effector mechanisms. , 1987, Cellular immunology.

[28]  S. Keshava,et al.  Epitope-specific regulation. II. A bistable, Igh-restricted regulatory mechanism central to immunologic memory , 1982, The Journal of experimental medicine.

[29]  J. Berzofsky,et al.  Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine , 1986, The Journal of experimental medicine.

[30]  B. McGinn,et al.  Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants , 1987, Nature.